Vitamin C Shows Promise in Pre‑Leukemia Trial, but More Research Is Needed

When researchers handed out 1,000 mg of oral vitamin C a day to people living with early‑stage blood disorders, they weren’t expecting a miracle. Still, the numbers that emerged from the EVIVA phase‑2 trial were hard to ignore.

The study enrolled 109 adults who had either clonal cytopenia of undetermined significance (CCUS)—a kind of precancerous blood condition—or myelodysplastic syndrome (MDS), a disorder that can morph into acute myeloid leukemia. Participants were split, in a double‑blind fashion, into two groups: one took the vitamin supplement for a full year, the other received a placebo that looked identical.

At baseline, more than half of the volunteers were actually low in vitamin C. After twelve months, those on the supplement saw their blood levels bounce back to normal, while the placebo group stayed deficient. That alone was encouraging, but the researchers dug deeper.

People who took vitamin C reported fewer adverse events during the treatment period and in the months that followed. Blood tests also revealed subtle shifts in cytokines—those messenger proteins that coordinate immune responses. The shifts lined up with what the investigators think is a dampening of the inflammatory pathways that help abnormal blood cells proliferate.

“We observed that vitamin C correlates with a change in inflammatory signaling that aligns with a better outcome,” explained Kirsten Grønbæk, a hematologist at the University of Copenhagen who led the work. She was quick to add, however, that the picture is probably more complex than a single nutrient acting alone.

The most striking signal came from an exploratory survival analysis. Roughly three years after the trial began, a noticeably higher proportion of the vitamin‑C group were still alive compared with the placebo cohort. Importantly, the study did not show a statistically significant slowdown in the growth of the abnormal blood‑cell clones, nor did it prove that vitamin C can outright prevent leukemia.

Scientists have long been intrigued by vitamin C’s relationship with the enzyme TET2, a key player in DNA demethylation and gene regulation. Mutations in TET2 are common in myeloid cancers, and laboratory work suggests that vitamin C can boost the enzyme’s activity. Whether this biochemical boost translates into the modest survival edge seen in the trial remains an open question.

Independent voices echo cautious optimism. Dr. Lucy Hooper, a general practitioner not involved in the study, noted, “There’s a plausible biological explanation—vitamin C is a co‑factor for TET2, which is often disrupted in these disorders.” Yet she warned that the trial was small; only 44 participants completed the full year of supplementation, and the primary endpoint—reducing the clone size—was not met.

Despite the limitations, the investigators view the findings as a stepping stone toward “cancer interception,” an approach that aims to intervene before a full‑blown malignancy takes hold. A phase‑3 trial is already in the planning stages, with hopes of launching in early 2027, and further subgroup analyses are slated for presentation at the 2026 American Society of Hematology meeting.

For now, the take‑away is measured: correcting a vitamin C deficiency is easy, cheap, and generally safe, and it might buy patients a little extra time. But until larger, rigorously designed studies confirm the benefit, vitamin C should be seen as a promising lead—not a proven therapy—for those living with precancerous blood conditions.